{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:56:04Z","timestamp":1793382964927,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171794"],"award-info":[{"award-number":["82171794"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071827"],"award-info":[{"award-number":["82071827"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971532"],"award-info":[{"award-number":["81971532"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004610","name":"Science and Technology Support Program of Jiangsu Province","doi-asserted-by":"publisher","award":["JSDW202203"],"award-info":[{"award-number":["JSDW202203"]}],"id":[{"id":"10.13039\/501100004610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Rapid progressive interstitial lung disease (RP-ILD) is the leading cause of anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis (anti-MDA5\n                      <jats:sup>+<\/jats:sup>\n                      DM) related death. Elevated serum B-cell activating factor (BAFF) levels have been implicated in connective tissue diseases associated ILD. Here, we evaluate whether BAFF could be a prognostic biomarker for predicting RP-ILD in anti-MDA5\n                      <jats:sup>+<\/jats:sup>\n                      DM patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Serums were collected from 39 patients with anti-MDA5\n                      <jats:sup>+<\/jats:sup>\n                      DM (20 with RP-ILD and 19 with non-RP-ILD), 20 antisynthase syndrome (ASS) patients and 20 healthy controls (HC). BAFF concentration was measured by an enzyme-linked immunosorbent assay.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum BAFF level was higher in anti-MDA5\n                      <jats:sup>+<\/jats:sup>\n                      DM patients than those in ASS patients and HC (3882.32\u2009\u00b1\u20091880.09\n                      <jats:italic>vs.<\/jats:italic>\n                      2540.89\u2009\u00b1\u20091403.04 and 2486.28\u2009\u00b1\u2009767.97\u00a0pg\/mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0056 and 0.0038, respectively). Within anti-MDA5\n                      <jats:sup>+<\/jats:sup>\n                      DM groups, RP-ILD patients exhibited higher BAFF concentration than non-RP-ILD group (4549.78\u2009\u00b1\u20091839.97\n                      <jats:italic>vs.<\/jats:italic>\n                      3297.28\u2009\u00b1\u20091794.69\u00a0pg\/mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). The BAFF concentration was positively correlated with levels of C-reactive protein (CRP), dehydrogenase (LDH) and cytokeratin (CK) in anti-MDA5\n                      <jats:sup>+<\/jats:sup>\n                      DM patients (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.350,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.035;\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.393,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016;\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.518,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001; respectively). The best cut-off value of BAFF concentration was 2971.5\u00a0pg\/mL by ROC curve (AUC area\u2009=\u20090.690,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.045) and BAFF\u2009&gt;\u20092971.5\u00a0pg\/mL was an independent risk factor for RP-ILD using multivariate analysis (OR\u2009=\u20099.389, 95% CI\u2009=\u20091.609\u201454.769;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Serum BAFF could be a useful prognostic biomarker for early detecting RP-ILD risk in anti-MDA5\n                      <jats:sup>+<\/jats:sup>\n                      DM patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-024-03153-6","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T21:01:51Z","timestamp":1713474111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis"],"prefix":"10.1186","volume":"19","author":[{"given":"Yumeng","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiao","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaojia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5160-2023","authenticated-orcid":false,"given":"Wenfeng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"issue":"5","key":"3153_CR1","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571\u20136.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"3153_CR2","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/art.24621","volume":"60","author":"S Sato","year":"2009","unstructured":"Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193\u2013200.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"3153_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","volume":"49","author":"R Nakashima","year":"2010","unstructured":"Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49(3):433\u201340.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"3153_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","volume":"147","author":"Y Hamaguchi","year":"2011","unstructured":"Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147(4):391\u20138.","journal-title":"Arch Dermatol"},{"issue":"7","key":"3153_CR5","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","volume":"51","author":"T Koga","year":"2012","unstructured":"Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012;51(7):1278\u201384.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3153_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/diagnostics12010045","volume":"12","author":"M Kumric","year":"2021","unstructured":"Kumric M, Zivkovic PM, Ticinovic Kurir T, Vrdoljak J, Vilovic M, Martinovic D, et al. Role of B-Cell Activating Factor (BAFF) in inflammatory bowel disease. Diagnostics (Basel). 2021;12(1):45.","journal-title":"Diagnostics (Basel)"},{"key":"3153_CR7","doi-asserted-by":"publisher","first-page":"156154","DOI":"10.1016\/j.cyto.2023.156154","volume":"164","author":"H Singh","year":"2023","unstructured":"Singh H, Kumar U, Senapati S. Translational implications of humoral and cellular immune dysfunction in granulomatosis with polyangiitis. Cytokine. 2023;164:156154.","journal-title":"Cytokine"},{"key":"3153_CR8","doi-asserted-by":"publisher","first-page":"666545","DOI":"10.3389\/fimmu.2021.666545","volume":"12","author":"M Saez Moya","year":"2021","unstructured":"Saez Moya M, Gutierrez-Cozar R, Punet-Ortiz J, Rodriguez de la Concepcion ML, Blanco J, Carrillo J, et al. Autoimmune B Cell repertoire in a Mouse Model of Sjogren\u2019s syndrome. Front Immunol. 2021;12:666545.","journal-title":"Front Immunol"},{"issue":"2","key":"3153_CR9","doi-asserted-by":"publisher","first-page":"103262","DOI":"10.1016\/j.autrev.2022.103262","volume":"22","author":"V Erazo-Martinez","year":"2023","unstructured":"Erazo-Martinez V, Tobon GJ, Canas CA. Circulating and skin biopsy-present cytokines related to the pathogenesis of cutaneous lupus erythematosus. Autoimmun Rev. 2023;22(2):103262.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"3153_CR10","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.3390\/ijms24032336","volume":"24","author":"G Kumar","year":"2023","unstructured":"Kumar G, Axtell RC. Dual role of B cells in multiple sclerosis. Int J Mol Sci. 2023;24(3):2336.","journal-title":"Int J Mol Sci"},{"key":"3153_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12890-015-0105-0","volume":"15","author":"T Hamada","year":"2015","unstructured":"Hamada T, Samukawa T, Kumamoto T, Hatanaka K, Tsukuya G, Yamamoto M, et al. Serum B cell-activating factor (BAFF) level in connective tissue disease associated interstitial lung disease. BMC Pulm Med. 2015;15:110.","journal-title":"BMC Pulm Med"},{"key":"3153_CR12","doi-asserted-by":"publisher","first-page":"1066111","DOI":"10.3389\/fmed.2022.1066111","volume":"9","author":"Y Wang","year":"2022","unstructured":"Wang Y, Xie X, Zheng S, Du G, Chen S, Zhang W, et al. Serum B-cell activating factor and lung ultrasound B-lines in connective tissue disease related interstitial lung disease. Front Med (Lausanne). 2022;9:1066111.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"3153_CR13","doi-asserted-by":"publisher","first-page":"R168","DOI":"10.1186\/ar4352","volume":"15","author":"A Francois","year":"2013","unstructured":"Francois A, Chatelus E, Wachsmann D, Sibilia J, Bahram S, Alsaleh G, et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther. 2013;15(5):R168.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"3153_CR14","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/1346-8138.15117","volume":"46","author":"T Matsushita","year":"2019","unstructured":"Matsushita T, Kobayashi T, Kano M, Hamaguchi Y, Takehara K. Elevated serum B-cell activating factor levels in patients with dermatomyositis: association with interstitial lung disease. J Dermatol. 2019;46(12):1190\u20136.","journal-title":"J Dermatol"},{"issue":"1","key":"3153_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/rheumatology\/keac234","volume":"62","author":"N Shen","year":"2022","unstructured":"Shen N, Zhou X, Jin X, Lu C, Hu X, Zhang Y, et al. MDA5 expression is associated with TGF-\u03b2-induced fibrosis: potential mechanism of interstitial lung disease in anti-MDA5 dermatomyositis. Rheumatology (Oxford). 2022;62(1):373\u201383.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"3153_CR16","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.3899\/jrheum.140977","volume":"42","author":"N Kobayashi","year":"2015","unstructured":"Kobayashi N, Kobayashi I, Mori M, Sato S, Iwata N, Shigemura T, et al. Increased serum B cell activating factor and a proliferation-inducing ligand are associated with interstitial lung disease in patients with juvenile dermatomyositis. J Rheumatol. 2015;42(12):2412\u20138.","journal-title":"J Rheumatol"},{"issue":"1","key":"3153_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13075-018-1650-8","volume":"20","author":"O Krystufkova","year":"2018","unstructured":"Krystufkova O, Hulejova H, Mann HF, Pecha O, Putova I, Ekholm L, et al. Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis. Arthritis Res Ther. 2018;20(1):158.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"3153_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/art.41566","volume":"73","author":"T Gono","year":"2021","unstructured":"Gono T, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Ikeda K, et al. Risk prediction modeling based on a combination of initial serum biomarker levels in polymyositis\/dermatomyositis-associated interstitial lung disease. Arthritis Rheumatol. 2021;73(4):677\u201386.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3153_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10067-015-3139-z","volume":"35","author":"Y Xu","year":"2016","unstructured":"Xu Y, Yang CS, Li YJ, Liu XD, Wang JN, Zhao Q, et al. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis. Clin Rheumatol. 2016;35(1):113\u20136.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3153_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.55563\/clinexprheumatol\/gtybu5","volume":"40","author":"L Feng","year":"2022","unstructured":"Feng L, Wang H, Zhao Y, Zhao T, Zhang J, Huang F, et al. Clinical manifestations and outcome of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody positive patients with interstitial lung disease. Clin Exp Rheumatol. 2022;40(1):97\u2013103.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"3153_CR21","doi-asserted-by":"publisher","first-page":"260","DOI":"10.55563\/clinexprheumatol\/ohsmuj","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhu L, Ju B, Luo J, Li Q, Lv X, et al. Alterations of peripheral blood B cell subsets in Chinese patients with adult idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2022;40(2):260\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"3153_CR22","doi-asserted-by":"publisher","first-page":"820163","DOI":"10.3389\/fimmu.2021.820163","volume":"12","author":"C He","year":"2021","unstructured":"He C, Li W, Xie Q, Yin G. Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis: a systematic review. Front Immunol. 2021;12:820163.","journal-title":"Front Immunol"},{"issue":"2","key":"3153_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1136\/ard.62.2.168","volume":"62","author":"X Mariette","year":"2003","unstructured":"Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren\u2019s syndrome. Ann Rheum Dis. 2003;62(2):168\u201371.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3153_CR24","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1136\/ard.2003.018663","volume":"63","author":"W Stohl","year":"2004","unstructured":"Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Roschke V, et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis. 2004;63(9):1096\u2013103.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3153_CR25","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/art.21526","volume":"54","author":"T Matsushita","year":"2006","unstructured":"Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 2006;54(1):192\u2013201.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"3153_CR26","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1093\/rheumatology\/kes080","volume":"51","author":"JL Vosters","year":"2012","unstructured":"Vosters JL, Roescher N, Polling EJ, Illei GG, Tak PP. The expression of APRIL in Sjogren\u2019s syndrome: aberrant expression of APRIL in the salivary gland. Rheumatology (Oxford). 2012;51(9):1557\u201362.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3153_CR27","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/ard.2008.091405","volume":"68","author":"O Krystufkova","year":"2009","unstructured":"Krystufkova O, Vallerskog T, Helmers SB, Mann H, Putova I, Belacek J, et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis. 2009;68(6):836\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"1\u20132","key":"3153_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jneuroim.2012.04.006","volume":"249","author":"A Baek","year":"2012","unstructured":"Baek A, Park HJ, Na SJ, Shim DS, Moon JS, Yang Y, et al. The expression of BAFF in the muscles of patients with dermatomyositis. J Neuroimmunol. 2012;249(1\u20132):96\u2013100.","journal-title":"J Neuroimmunol"},{"issue":"3","key":"3153_CR29","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3899\/jrheum.120555","volume":"40","author":"CM Lopez De Padilla","year":"2013","unstructured":"Lopez De Padilla CM, McNallan KT, Crowson CS, Bilgic H, Bram RJ, Hein MS, et al. BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies. J Rheumatol. 2013;40(3):294\u2013302.","journal-title":"J Rheumatol"},{"issue":"5","key":"3153_CR30","doi-asserted-by":"publisher","first-page":"e122728","DOI":"10.1172\/jci.insight.122728","volume":"4","author":"PJ Maglione","year":"2019","unstructured":"Maglione PJ, Gyimesi G, Cols M, Radigan L, Ko HM, Weinberger T, et al. BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency. JCI Insight. 2019;4(5):e122728.","journal-title":"JCI Insight"},{"key":"3153_CR31","doi-asserted-by":"publisher","first-page":"622114","DOI":"10.3389\/fimmu.2020.622114","volume":"11","author":"EM Matson","year":"2020","unstructured":"Matson EM, Abyazi ML, Bell KA, Hayes KM, Maglione PJ. B cell dysregulation in common variable immunodeficiency interstitial lung disease. Front Immunol. 2020;11:622114.","journal-title":"Front Immunol"},{"issue":"4","key":"3153_CR32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.42308","volume":"75","author":"L Xu","year":"2023","unstructured":"Xu L, You H, Wang L, Lv C, Yuan F, Li J, et al. Identification of three different phenotypes in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis patients: implications for prediction of rapidly progressive interstitial lung disease. Arthritis Rheumatol. 2023;75(4):609\u201319.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3153_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/rheumatology\/keab305","volume":"61","author":"W Wu","year":"2021","unstructured":"Wu W, Xu W, Sun W, Zhang D, Zhao J, Luo Q, et al. Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study. Rheumatology (Oxford). 2021;61(1):230\u20139.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03153-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03153-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03153-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T21:02:51Z","timestamp":1713474171000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03153-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3153"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03153-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3220730\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]},"assertion":[{"value":"13 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the First Affiliated Hospital of Nanjing Medical University Committee on Ethics (ID: 2020-SR-265). Informed consent was obtained from each study participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}